Olmesartan Medoxomilo Teva (Olmesartan Medoxomil)

Olmesartan medoxomil is an ARB used to manage conditions related to the renin‑angiotensin system.

• Hypertension: lowers systolic and diastolic blood pressure to target levels.
• Essential hypertension: improves long‑term cardiovascular outcomes.
• High blood pressure: assists patients in achieving recommended blood‑pressure goals.

• Olmesartan medoxomil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from binding. This inhibition stops vasoconstriction and aldosterone release, leading to relaxation of vascular smooth muscle, reduced peripheral resistance, and a decrease in blood pressure.

Olmesartan medoxomil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness: transient light‑headedness, especially after the first dose.
• Headache: mild to moderate intensity.
• Fatigue: feeling of tiredness without exertion.
• Abdominal pain: mild discomfort in the stomach area.
• Nasal congestion: stuffy nose or sinus pressure.
• Back pain: occasional soreness in the lumbar region.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or throat requiring immediate medical attention.
• Hyperkalemia: elevated potassium levels that may cause cardiac arrhythmia.
• Acute renal impairment: sudden decline in kidney function.
• Severe hypotension: markedly low blood pressure leading to fainting.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Allergic reactions: rash, itching, or urticaria.

Before initiating therapy with Olmesartan medoxomil, consider the following safety measures.

• Blood pressure monitoring: check regularly to ensure therapeutic response.
• Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with kidney disease.
• Electrolyte surveillance: monitor potassium levels to avoid hyperkalemia.
• Hepatic impairment caution: use with care in patients with severe liver dysfunction.
• Pregnancy and lactation warning: avoid use during pregnancy; discuss risks with a healthcare professional if breastfeeding.
• Store at room temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Olmesartan medoxomil can interact with several drug classes; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): combined use may increase risk of renal impairment and hyperkalemia.
• Potassium‑sparing diuretics: may cause dangerous elevations in serum potassium.
• ACE inhibitors: concurrent use can lead to additive risk of angioedema and hyperkalemia.
• Lithium: increased lithium levels and potential toxicity.
• NSAIDs (high‑dose or chronic): may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: may enhance blood‑pressure lowering effect, requiring dose adjustment.
• CYP450 inhibitors (e.g., azole antifungals): may modestly increase olmesartan exposure.
• Antihypertensive agents (beta‑blockers, calcium‑channel blockers): additive hypotensive effect, monitor for symptomatic hypotension.